Olmesartan comes through for Daiichi Sankyo
This article was originally published in Scrip
Sales and profits at Daiichi Sankyo came in ahead of the company's own forecasts for the first half to September 30th, helped by strong US sales, non-operating gains from the valuation of Ranbaxy's foreign exchange derivatives and the one-off sale of investment securities.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.